Manufacturing
Pharmaceuticals & Medical Devices
World's largest generic-medicine producer by volume. Three separate PLI schemes (bulk drugs, finished pharma, medical devices); FDI 100% greenfield / 74% brownfield.
Highlights
- PLI for Bulk Drugs / KSMs / APIs — ₹6,940 crore outlay; production-linked incentive of 5–20% on incremental sales.
- PLI for Pharmaceuticals (finished formulations + biopharmaceuticals + complex generics) — ₹15,000 crore.
- PLI for Medical Devices — ₹3,420 crore.
- Bulk Drug Parks scheme — ₹3,000 crore for three parks (Himachal Pradesh, Gujarat, Andhra Pradesh) with common infrastructure.
- India supplies ~20% of the world's generic medicines by volume; over 50% of global vaccine supply.
Flagship policies & schemes
- Open
Bulk Drug Parks scheme
₹3,000 crore for three bulk drug parks with shared infrastructure to reduce manufacturing cost of bulk drugs.
Notable infrastructure
Bulk Drug Park — Himachal Pradesh
Manufacturing park
Bulk Drug Park — Gujarat
Manufacturing park
Bulk Drug Park — Andhra Pradesh
Manufacturing park
Sources
- Department of Pharmaceuticals — Make in India· ministry portal
- PIB — PLI Schemes for 14 sectors· pib release
- Consolidated FDI Policy· policy doc
Want to suggest a correction? See our methodology or tell us.